NTRK2 and Cognitive impairment: Having shown that the BDNF-TrkB pathway in DG is causally involved in ELS-induced cognitive deficits, we then evaluated the potential therapeutic effects when targeting at the pathway, by systemic administration of TrkB receptor antagonist (ANA-12) and agonist (7,8-DHF).